BARCELONA, Spain - InspireMD, Ltd. announced today the completion of enrolment for the MAGICAL trial (MGuard(TM) in Acute Myocardial). The trial was designed to confirm the clinical feasibility, safety and performance of MGuard when used during Primary PCI in STEMI patients.
The MAGICAL trial is a multicenter, prospective, single arm, 60 patients study (Principal investigator: Dr. Dariusz Dudek, Jagiellonian University, Krakow, Poland). Primary end-points are incidence of complete ST segment resolution measured 60 minutes post procedure and incidence of TIMI 3 flow after PCI. Main secondary endpoints are myocardial blush grade and MACE (major adverse cardiac events) at discharge, 30 days and 6 months.
“I am very pleased and excited we reached this milestone” said Dr. Dariusz Dudek, the MAGICAL Study Chief Investigator, from Jagiellonian University in Krakow. “From the data collected so far, primary PCI for STEMI patients using MGuardTM seems highly safe and effective”.
To date, TIMI flow 3 is 91%, MBG 3 (Myocardial Blush Grade) is 74%, Complete ST Resolution is 63%. MACE at discharge is 0% and 30 days MACE to date is 0% as well.
“This important milestone is getting us closer to confirm MGuard’s important role in the treatment of acute MI patients, by providing a comprehensive solution to the distal embolization threat” said Eli Bar, CTO and VP R&D at InspireMD. “So far, the MAGICAL Trial results are confirming what we had experienced in cath-labs around the world; that the MGuardTM performs well and delivers extra safety for the patients”.
A presentation of the updated results of the MAGICAL trial by Dr. Dariusz Dudek will be given at the InspireMD Cocktail Reception, May 21st at 18:30 at the Hilton Diagonal Mar, next to the EuroPCR conference CCIB Conference center. The Cocktail Reception and Debate: “What is the Best Strategy in Acute MI?” will be chaired by the world renowned opinion leader, Martin Leon MD.
About MGuard(TM) Coronary
MGuard(TM) presents a novel combination of a coronary stent merged with an embolic protection. The embolic protection is comprised of an ultra-thin polymer mesh sleeve that wraps the stent. The protective sleeve is composed of a micron-level-fiber which is knit in order to ensure flexibility while retaining the strength characteristics of the fiber material. The sleeve is designed to expand seamlessly when the stent is deployed, without effecting the structural integrity of the stent. The MGuard(TM) coronary stent provides permanent embolic protection, without complicating deliverability. Reduced injury to the vessel as a result of diffused stent pressure is a benefit of the sleeve which may lead to lower risk of restenosis. MGuard(TM) is CE Mark approved.
The MGuard(TM) Coronary’s innovative concept has enjoyed an enthusiastic welcome from leading interventional cardiologists around the world.
About InspireMD
InspireMD Ltd. is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD’s mission is to utilize its proprietary technology to make its products the industry standard for stents and to provide a superior solution to the key clinical issues of current stenting: restenosis, embolic showers, and late thrombosis.
In addition to providing embolic protection and minimizing arterial injury, this promising technology can be an effective and uniform drug delivery mechanism with the help of the novel micron-level net for next generation drug eluting stents. InspireMD intends to pursue applications of this technology both for bare metal and drug eluting stents in coronary, carotid and peripheral artery procedures.
For further information visit: www.inspire-md.com
Contact: Jonina Ohayon Marketing Director Tel +972-52-5791120 jonina@inspire-md.com
Source: InspireMD
Contact: Jonina Ohayon, Marketing Director, Tel +972-52-5791120, jonina at inspire-md.com
Related Press Releases
Abbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV TrialSeptember 22nd, 2009 SAN FRANCISCO -
At One Year, XIENCE V Demonstrates:
- Statistical Superiority on Primary Endpoint of Target Lesion Failure, with a 38 Percent Reduction Compared to TAXUS
- 74 Percent Reduction in Stent Thrombosis (Blood Clots) Compared to TAXUS
- Low Event Rates across Multiple Subgroups of Complex Patients
Late-breaking data from the SPIRIT IV trial demonstrated that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System achieved superiority in the key safety and efficacy measures of target lesion failure (TLF) and target lesion revascularization (TLR) compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS) at one year. With 3,690 patients, the SPIRIT IV trial is one of the largest randomized clinical trials between two drug eluting stents.
InspireMD Announces the Enrollment of the 1st Patient in the MGuard(TM) Israeli Registry. InspireMD Will Also Sponsor a Satellite Program Breakfast Meeting at the TCT Conference on September 24th 2009 in the Moscone Exhibition Center in San FranciscoSeptember 22nd, 2009 SAN FRANCISCO - InspireMD, developers of MGuard(TM), announced today that the first patient has been enrolled in the Israeli MGuard(TM) Registry. MGuard(TM) was successfully implanted in Natanya, Israel, at the Laniado Hospital Cath Lab, managed by Dr.
Six Month Clinical Outcomes of Sahajanand Medical Technologies Supralimus - Sirolimus Eluting Stent presented at EuroPCR 09September 18th, 2009 BARCELONA, Spain, May 20, 2009 - Six months Clinical outcome of Sahajanand Medical Technologies Supralimus-Sirolimus Eluting stent with Bioabsorbable Polymer was presented at EuroPCR 2009. This analysis was performed as a part of the prospective of E-Series Multicenter Registry.
Ramadhan Tips for Cardiac CareSeptember 4th, 2009 Myocardial infarction or heart attack is known to be the number killer worldwide and a major cause of disability. During the Ramadhan period, patients with heart problems are encouraged to take extra care of their eating habit to avoid potential heart attack.
Sanofi Aventis: Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary SyndromesAugust 30th, 2009 PARIS -
- SEPIA-ACS Multiple-Dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The Lancet -
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use in 4 out of the 5 otamixaban tested doses, versus standard UFH/eptifibatide combination in [non-ST] ACS patients suitable for invasive strategy. The results of the SEPIA-ACS1/ TIMI-42 were presented today at the plenary session of the Annual European Society of Cardiology congress in Barcelona and simultaneously published online in The Lancet.
Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary SyndromesAugust 29th, 2009 PARIS -
- SEPIA-ACS Multiple-dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The Lancet
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use in 4 out of the 5 otamixaban tested doses, versus standard UFH/eptifibatide combination in [non-ST] ACS patients suitable for invasive strategy. The results of the SEPIA-ACS1/ TIMI-42 were presented today at the plenary session of the Annual European Society of Cardiology congress in Barcelona and simultaneously published online in The Lancet.
Accumetrics, Inc. Announces 1000th Patient Enrolled in GRAVITAS TrialMay 12th, 2009 SAN DIEGO - Accumetrics, Inc. announces that it has enrolled its 1,000th patient into its landmark clinical trial, GRAVITAS (Gauging Responsiveness with A VerifyNow(R) Assay Impact on Thrombosis And Safety).
InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 PatientsMay 5th, 2009 TEL AVIV, Israel - InspireMD, developers of MGuard(TM), announced today that the first patient has been enrolled in the iMOS registry. MGuard(TM) was successfully implanted at the General University Hospital in Prague; the procedure was performed by Dr.
Novagali Pharma Completed a New Phase II With Cyclokat(R) in Dry EyeApril 14th, 2009 EVRY, France - Novagali Pharma, a French pharmaceutical ophthalmic company, today announces successful completion of a new Phase II clinical study with Cyclokat(R), its formulation of Cyclosporine. The results demonstrate statistically significant improvement with signs and symptoms in patients suffering from moderate-to-severe dry eye syndrome.
World-First Launch of New Heart DrugApril 7th, 2009 LONDON - Britons First to Benefit From Latest Heart Tablet Prasugrel (Efient(R) Black Triangle Drug)
UK patients are the first to benefit from the launch of a new heart drug prasugrel (Efient), following authorisation by the European Medicines Agency (EMEA). The availability of prasugrel offers fresh hope to patients who have unstable angina or have had a heart attack - known as Acute Coronary Syndromes (ACS)(1) - who undergo a PCI* procedure (angioplasty) to re-open a narrowed or blocked artery.
Related News
Lowered HRT use may have led to fewer heart attacks in womenApril 25th, 2009 WASHINGTON - With decline in the use of hormone replacement therapy (HRT) to treat menopause symptoms, the rate of myocardial infarctions, or heart attacks, has also dropped, a new study has found. However, there has been no decrease in the rate of strokes, the study published in the May issue of the journal Medical Care noted.
Scientists identify novel target for heart failure therapyMarch 17th, 2009 WASHINGTON - Researchers from Thomas Jefferson University have identified a novel signalling pathway that can be a potential target for heart failure therapy. The pathway plays a significant role in the production of aldosterone, a hormone that promotes heart failure after a myocardial infarction.
Enrollment decreasing in Detroit Public SchoolsAugust 22nd, 2009 Enrollment decreasing in Detroit Public SchoolsHere's a look at the enrollment decline in the Detroit Public Schools:
—2003-2004: 150,415
—2004-2005: 141,148
—2005-2006: 130,580
—2006-2007: 118,394
—2007-2008: 108,145
—2008-2009: 94,054
—2009-2010: 83,777 (budgeted by district)
Sources: Council of the Great City Schools, Detroit Public Schools
CBSE class XII results to be announced todayMay 22nd, 2009 NEW DELHI - The Central Board of Secondary Education (CBSE) will announce the results of class-XII exam today. Over 6.3 lakh students had appeared for the exams that were held in March.
Cigna 2nd-quarer profit rises 60 percent, company raises outlook but enrollment fallsJuly 30th, 2009 Cigna 2Q profit climbs, enrollment fallsINDIANAPOLIS — Health insurer Cigna Corp. said Thursday its second-quarter profit jumped 60 percent on a more favorable interest rate and other items but, like other major health insurers, enrollment tumbled as employers cut jobs.
Novel target for migraine prevention identifiedApril 29th, 2009 WASHINGTON - Researchers have found a potential target for developing new treatment for acute migraine attacks. The new research by Addex Pharmaceuticals showed that targeting glutamate receptor 'mGluR5', the most common neurotransmitter in the brain, could prevent migraines.
German court: Demjanjuk trial start date not before November at the earliestSeptember 10th, 2009 German court: Demjanjuk trial not before NovemberMUNICH — A German court expects John Demjanjuk's trial on charges of being an accessory to the murder of thousands at a Nazi death camp to begin in November at the earliest. The court in Munich said in a statement Thursday that it would announce its decision on the trial date at the end of September and make no further statements beforehand.
Sterlite Industries (India) Limited notice of FY 2009 resultsApril 25th, 2009 MUMBAI - Sterlite Industries (India) Limited, India's leading diversified mining and metal company with interests and operations in aluminium, copper, zinc and lead and commercial power, will announce its results for the fourth quarter and full year ended March 31 on April 28. The results will also be available on the company's website, www.sterlite-industries.com.
Obama: US-China relations will shape 21st century, calls for shared responsibilityJuly 27th, 2009 Obama: US-China relations will shape 21st centuryWASHINGTON — President Barack Obama says the U.S.-China relationship will mold the 21st century. The president spoke Monday morning to the opening session of two days of critical talks with top Beijing leaders on issues ranging from the troubled world economy to climate change and nuclear proliferation.
Health insurer WellPoint reports 2nd quarter profit drop, shares fall on enrollment lossJuly 29th, 2009 WellPoint 2Q profit, enrollment tumbleINDIANAPOLIS — Shares of WellPoint Inc. tumbled Wednesday after the health insurer reported a second-quarter profit drop and enrollment that slid further than analysts expected.
